| Phase I |
6
|
(11%)
|
| Phase II |
13
|
(24%)
|
| Phase III |
25
|
(45%)
|
| Phase IV |
10
|
(18%)
|
| Observational study |
1
|
(2%)
|
| Total |
55
|
(100%)
|
| Statistical support in the development of the protocol |
7
|
(13%)
|
| Data entry |
11
|
(20%)
|
| Data management |
20
|
(44%)
|
| Statistical analysis planning |
48
|
(87%)
|
| Analysis/ programming |
53
|
(96%)
|
| Statistical support in regulatory submission |
5
|
(9%)
|
| All studies |
55
|
(100%)
|
Currently ongoing studies involve the following
Malaria, COPD, immuno-suppression after transplantation, lung cancer, asthma,
pancreatic enzyme replacement therapy, medical devices, diabetes, hypertension,
pulmonary arterial hypertension, sepsis, psoriasis, HIV, cystic fibrosis, hepatitis C,
volume replacement therapy, infectious diseases, anemia, Alzheimer's disease,
neuropathic pain and others.
|
